The short version of c-Met receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Smooth surfaces of mica, gold, various polymers and solid gelatin solutions do not stay apart when their separating becomes small enough – on the order of 1–10 nm. The equation describing these attractions was predicted in the 1930s by De Boer and Hamaker:
== Awards and honours == 1964: Blue Key Award: University of Southern California, Los Angeles, USA. 1965–1970: Medical Research Scholar Award (Canada). 1977: USSR Academy of Sciences invitation to lecture in Academies/Universities in Moscow, Pouschino, Novosibirsk, Tashkent, and Leningrad as a visiting professor. 1977: Nuffield Foundation Award, U.K. 1977: Member of the High Table, King's College, University of Cambridge, U.K. 1981–1982: Chairman: Biological Chemistry Division, Chemical Institute of Canada. 1982: Invited to speak at the 56th Nobel Symposium on Inorganic Biochemistry under the auspices of the Nobel Foundation, Sweden. 1984 : Visiting Professor : Université de Paris Nord, Paris, France. 1986: Elected Fellow of the Chemical Institute of Canada (FCIC). 1988: Chinese Academy of Sciences invitation to lecture in Academies/Universities in Beijing, Guiyang and Hangzhou as Visiting Professor. 1996: Commencement Speaker, Akdeniz University, Antalya (Turkey). 1998: Honorary Professor, Ambedkar Center for Biomedical Research, University of Delhi, New Delhi, India. 2000: Visiting Professor (European Union) University of Ioannina, Greece. 2002: Visiting Professor, National University of Singapore, Singapore. 2003: Research Institute (SickKids) Citizenship Award of the Year. 2004: Received R. C. Mehrotra Award for Science from the Vice President of India at the International Conference on Chemistry Biology Interface: Synergistic New Frontiers, New Delhi, India.
Cold agglutinin disease (CAD) is a rare autoimmune disease characterized by the presence of high concentrations of circulating cold sensitive antibodies, usually IgM and autoantibodies that are also active at temperatures below 30 °C (86 °F), directed against red blood cells, causing them to agglutinate and undergo lysis. It is a form of autoimmune hemolytic anemia, specifically one in which antibodies bind red blood cells only at low body temperatures, typically 28–31 °C. When affected people's blood is exposed to cold temperatures (32 °F (0 °C; 273 K) to 50 °F (10 °C; 283 K)), certain proteins that normally attack bacteria (IgM antibodies) attach themselves to red blood cells and bind them together into clumps (agglutination). This eventually causes red blood cells to be prematurely destroyed (hemolysis) leading to anemia and other associated signs and symptoms. Cold agglutinin disease can be primary (unknown cause) or secondary, due to an underlying condition such as an infection, another autoimmune disease, or certain cancers. Treatment depends on many factors including the severity of the condition, the signs and symptoms present in each person, and the underlying cause. Cold agglutinin disease was first described in 1957.
== Characterization == Designing effective antimicrobial surfaces demands an in-depth understanding of the initial microbe-surface adhesion mechanisms. Scanning electron microscopy (SEM) is used for nonliving samples. Bacterial colony forming unit (CFU) counting requires overnight incubation and detects bacteria that readily grow on solid media. Molecular dynamics (MD) simulation can be used to minimize the number of experiments with engineered substrates, with the quantification of time-lapse fluorescence microscopy images that can be processed in an hour. Contact angle measurements can be used to characterize micro/nano-pillars use for rupturing cell walls. The analysis of the zeta potential by the streaming potential method of either an antimicrobial coating or a self-disinfectant material in contact with an aqueous environment, or by electrophoretic light scattering of nanoparticle dispersions of antibacterial additives reveal information about surface and interfacial charge and let predict the electrostatic attraction or repulsion of microorganisms.
When an ice road is part of a winter road, as is commonly the case, its design and construction is comprised within the overall road planning, i.e. in conjunction with the over-land segments. Either way, factors that need to be addressed before construction include the following:
Sources: en.wikipedia.org
== Regulation of PTH secretion == Secretion of parathyroid hormone is determined chiefly by serum ionized calcium concentration through negative feedback. Parathyroid cells express calcium-sensing receptors on the cell surface. PTH is secreted when [Ca2+] is decreased (calcitonin is secreted when serum calcium levels are elevated). The G-protein-coupled calcium receptors bind extracellular calcium and may be found on the surface on a wide variety of cells distributed in the brain, heart, skin, stomach, C cells, and other tissues. In the parathyroid gland, high concentrations of extracellular calcium result in activation of the Gq G-protein coupled cascade through the action of phospholipase C. This hydrolyzes phosphatidylinositol 4,5-bisphosphate to liberate intracellular messengers IP3 and diacylglycerol (DAG). Ultimately, these two messengers result in a release of calcium from intracellular stores into the cytoplasmic space. Hence a high extracellular calcium concentration leads to an increase in the cytoplasmic calcium concentration. In contrast to the mechanism that most secretory cells use, this high cytoplasmic calcium concentration inhibits the fusion of vesicles containing granules of preformed PTH with the membrane of the parathyroid cell, and thus inhibits release of PTH. In the parathyroids, magnesium serves this role in stimulus-secretion coupling. A mild decrease in serum magnesium levels stimulates the reabsorptive activity PTH has on the kidneys.
Propofol is the active component of an intravenous anesthetic used for induction and maintenance of general anesthesia. Propofol was first marketed under the brand name Diprivan. Intravenous administration is used to induce unconsciousness, after which anesthesia may be maintained using a combination of medications. Propofol is manufactured as part of a sterile injectable emulsion using soybean oil and lecithin, which gives it a white milky color. Compared to other anesthetics, recovery from propofol-induced anesthesia is generally quick and infrequently associated with such side effects as drowsiness, nausea, vomiting. Propofol may be used before diagnostic procedures requiring anesthesia, in the management of refractory status epilepticus, and for induction or maintenance of anesthesia before and during surgery. It may be administered as a bolus or an infusion, or as a combination of the two. First synthesized in 1973 by John B. Glen, a British veterinary anesthesiologist working for Imperial Chemical Industries (ICI, later AstraZeneca), propofol was introduced for therapeutic use as a lipid emulsion in the United Kingdom and New Zealand in 1986. Propofol (Diprivan) received FDA approval in October 1989. It is on the World Health Organization's List of Essential Medicines.
==== X-Ray Absorption Spectroscopy ==== X-Ray absorption spectroscopy (XAS) has been demonstrated as a technique for nuclear forensic investigations involving uranium speciation. Both the lower energy near-edge (XANES) and higher energy fine structure (EXAFS) analytical methods may be useful for this type of characterisation. Typically, XANES is employed to determine the oxidation state of the absorbing uranium atom, while EXAFS can be used to determine its local atomic environment. This spectroscopic method, when coupled with X-Ray diffraction (XRD), would be of most benefit to complex nuclear forensic investigations involving species of different oxidation states.
== External links == Metribolone at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Methyltrienolone - William Llewellyn's Anabolic.org Archived 2016-04-07 at the Wayback Machine
Sources: en.wikipedia.org
Fragrances are detected by the nose when the movement of inspired air contacts olfactory sensory neurons, which in humans, number between 6 and 10 million over a surface area of 2.5 cm2 (0.39 sq in) of olfactory epithelium. Fragrance signals are conveyed from the epithelium to the olfactory nerves, and then to the olfactory bulbs, which relay neural impulses about fragrance properties into the primary olfactory cortex of the brain. In the olfactory cortex, fragrance characteristics are integrated to evaluate the safety and appeal of compounds to be ingested, and to recognize environmental and social factors associated by memory with the fragrance.
== History == DOM was the first psychedelic of the DOx series to be discovered. It was first synthesized by Alexander Shulgin at Dow Chemical Company in 1963, who had had his first psychedelic experience, with mescaline (3,4,5-trimethoxyphenethylamine), in 1960. Shulgin personally tried DOM on January 4, 1964 and discovered its psychedelic effects. 2,4,5-Trimethoxyamphetamine (TMA-2; "DOMeO") had been synthesized by Bruckner in 1933, but its psychedelic effects were not described until Shulgin tried the compound and reported its effects in the scientific literature in 1964. Prior to this, 3,4,5-trimethoxyamphetamine (TMA; α-methylmescaline) had been synthesized by Hey in 1947, being found by him to produce euphoria, and was described by Peretz and colleagues in 1955 as clearly producing psychedelic effects. Following his discovery of DOM, Shulgin developed DOET and found that at low doses it was a remarkable "psychic energizer" without producing psychedelic effects at these doses. Dow Chemical Company decided to move forward with clinical trials of DOET as a potential pharmaceutical drug for such purposes. Shulgin and Dow Chemical Company filed a patent for DOET in 1966, although it was not published until 1970. Dow Chemical Company tasked Solomon H. Snyder at Johns Hopkins University with clinically studying DOET. In April 1967, following the banning of LSD in California in 1966, DOM emerged as a street drug and legal LSD alternative with the name "STP" (allegedly short for "Serenity, Tranquility, and Peace") in the Haight-Ashbury district in San Francisco.
== Plot == Timofey Berezin (Paddy Considine) works at a former top-secret, badly run and aged nuclear reprocessing facility plant in Skotoprigonyevsk-16, a former closed city and a naukograd. At the film's outset, he is exposed to radioactive contamination while selflessly trying to prevent a critical malfunction. The facility's managers tell him that his exposure was a survivable 100 rems, while accusing him of sabotage and suspending him without pay. Loyal coworkers, however, help Timofey discover the truth that he was exposed to 1,000 rems of radiation. Suffering from acute radiation poisoning, he has only days to live. Before Timofey's adoring wife, Marina (Radha Mitchell), is fully aware of his fate, he leaves for Moscow, on a mission to secure a better future for her and their young son. He hooks up with a small-time gangster, Shiv (Oscar Isaac), in hopes of finding a buyer for a selfmade canister of a little over 100 grams of weapons-grade plutonium salt he has stolen. It is 1995, only a few years after the dissolution of the Soviet Union, and they spend their time frequenting the hotels, nightclubs and private palaces of the new Moscow underworld, ricocheting between two rival crime lords (Nikolaj Lie Kaas and Steven Berkoff). However, what Timofey and Shiv never realize is that they are both caught in the same dilemma: trying to find a way free of a certain fate; hoping to do right by their loved ones before it is too late.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.